Universal reference book for medicines
Name of the preparation: BiKNU

Active substance: carmustine

Type: Antitumor preparation

Manufacturer: BRISTOL-MYERS SQUIBB (Italy)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

Antitumor agent of alkylating action from the group of nitrosourea derivatives.
It acts on the bases and phosphate groups of DNA, which leads to ruptures and crosslinks of its molecule. It is a cyclone-specific compound. The action of carmustine can also be related to the modification of proteins.
Rapidly metabolized in the liver with the formation of active metabolites.
Metabolites can persist in the blood plasma for several days.
Penetrates through the BBB.

It is mainly excreted by the kidneys in the form of metabolites - 60-70%, with feces - 1%, through the respiratory tract - 10%.

Brain tumors (glioblastoma, brain stem glioma, medulloblastoma, astrocytoma, ependymoma) metastasizing brain tumors;
multiple myeloma (in combination with prednisolone); lymphogranulomatosis (in combination with other drugs); non-Hodgkin's lymphomas.
Established individually, depending on the indications and stage of the disease, the state of the hematopoiesis system, the scheme of antitumor therapy.

From the hemopoietic system: often - myelodepression;
anemia is possible.
On the part of the digestive system: often - nausea, vomiting;
possible manifestations of hepatotoxicity - increased activity of transaminases, alkaline phosphatase, bilirubin level.
From the respiratory system: there may be infiltrates and / or foci of fibrosis in the lungs.

From the side of the urinary system: after prolonged use in high cumulative doses - progressive azotemia, a decrease in the size of the kidneys.

With rapid on / in the introduction: a burning sensation at the injection site is possible, as well as marked reddening of the skin and swelling of the conjunctiva within 2-4 hours.

Other: Neuroretinitis, chest pain, headache, allergic reactions, arterial hypotension, tachycardia are possible.

Hypersensitivity to carmustine.

Adequate and strictly controlled studies of the safety of the use of carmustine in pregnancy in humans have not been conducted.
There are data on the embryotoxic effect of carmustine in pregnancy in humans.
In experimental studies it was shown that carmustine exerts an embryotoxic effect in pregnancy in rats and rabbits and teratogenic action in rats at doses equivalent to the doses used in humans.

Women of childbearing age during the period of treatment are recommended to use reliable methods of contraception.

It is not known whether carmustine is excreted in breast milk.
If necessary, use during lactation should stop breastfeeding.
In the process of treatment, control of the picture of peripheral blood, liver function, kidney and X-ray examination of the lungs is necessary.
Since the distinguishing feature of carmustine is a delayed manifestation of the oppressive effect on the hematopoiesis, control of the pattern of peripheral blood should be carried out weekly for 6 weeks after the end of the application.
With simultaneous use with other drugs that cause myelodepression, additive inhibition of bone marrow function is possible;
with drugs that have a hepato- or nephrotoxic effect - an increase in manifestations of hepato- or nephrotoxicity.
[MSK] 01.04 in the RK is not registered.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!